Navigation Links
ATS Medical Participating in 44th Annual STS Annual Meeting
Date:1/24/2008

MINNEAPOLIS, Jan. 24 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI) is looking forward to its participation in the 44th Annual Meeting of the Society of Thoracic Surgeons (STS). The event runs January 28-30, 2008 in Fort Lauderdale, Florida, and serves as one of the year's key gatherings of cardiovascular surgeons from around the world.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

ATS Medical continues to broaden its exposure and relationships within the cardiac surgery community and the STS meeting provides an excellent opportunity to display the progress made in assembling an array of product offerings focused on meeting the evolving needs of cardiac surgeons. Featured products will include the company's flagship ATS Open Pivot(R) Heart Valve and our latest advancement, the ATS Open Pivot(R) AP360(TM). Recently approved in the US, the AP360 expands upon the fundamental strengths of the open pivot design by maximizing hemodynamic performance while incorporating a cuff design that will extend the valve's appeal to a broader spectrum of surgeon preferences.

ATS 3f(R) tissue heart valve products will be prominently featured. In-booth presentations on Monday, January 28th will include Dr. Richard Shemin, UCLA Medical Center, presenting a "Review of FDA Clinical Data with the ATS 3f(R) Aortic Bioprosthesis" and Professor Thierry Carrel, University Hospital of Berne, reporting on "Experience with the Sutureless ATS 3f Enable(TM) Aortic Bioprosthesis".

The ATS Simulus(R) annuloplasty product family, designed for the heart valve repair market segment, has expanded with the recent FDA approval of the ATS Simulus(R) Semi-Rigid Ring. This meeting will be the first market introduction of the semi rigid addition to the Simulus product line. The Simulus Semi Rigid ring includes the unique Flex-Zone(TM) anterior segment which respects the natural motion of the mitral annulus and its proximity to the aortic valve allowing for a safer, more physiologic valve repair.

Surgical treatment of cardiac arrhythmias continues to be a topic of great interest for surgeons and growing numbers find the ATS CryoMaze(TM) product line to be their therapy of choice. Dr. Harold Roberts, Florida Medical Center, will be presenting "CryoMaze Using Argon-Based Cryoablation is Highly Effective Therapy During Complex Valve Procedures" at the ATS booth on Tuesday, January 29th. In conjunction with East Carolina Heart Institute, ATS is sponsoring a scientific symposium focusing the treatment of atrial fibrillation, moderated by ATS Medical Director Dr. James L. Cox, and STS President Dr. W. Randolph Chitwood. Hands-on demonstrations of these market leading cryoablation technologies will be available at ATS Medical's booth #424.

About ATS Medical

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The company, global in scope, is headquartered in Minneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair, and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2006 and its most recent quarterly report on Form 10-Q.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4, 2008
2. Medical University of South Carolina (MUSC) and Halsey Institute Create Partnership Between Art and Science
3. Aircraft Medical: European Patent Hearing
4. A Fort Worth Couple Sues Huguley Memorial Medical Center
5. Study raises questions about diagnosis, medical treatment of ADHD
6. MHA Insurance Company Offers Financial Incentive to Physician Policyholders Who Use Electronic Medical Records
7. Struggling Medical Delivery System Impacts Hospitals and Physicians Hardest
8. Aircraft Medical Ready to Fight
9. VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer
10. Hollywood Presbyterian Medical Center Responds to ACLU Lawsuit
11. Former Sufferer of Rare Disease Called Musicogenic Epilepsy Thanks LIJ Medical Team That Ended Her Seizures and Gave Her Back the Gift of Music
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... outlet with a clinician-based audience, will be participating in Rare Disease Day events, ... Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... marketing, social media management, corporate communications, SEO and cause marketing, is opening an ... nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $47.6 billion ... estimates and forecasts for all the given segments on global as ...
(Date:2/23/2017)... February 23, 2017 The fast-growing cannabis ... the United States . According to the 2017 Legal ... is expected to create 283,422 jobs by 2020, with an ... the next four years. The accelerating pace of cannabis legalization ... of legal cannabis market, which will further create more business ...
(Date:2/23/2017)... , February 23, 2017 ... on the global market for intraoperative imaging, excerpts ... valued at US$ 513.9 million. According to the ... surging on the grounds of increasing adoption of ... field of diagnostic imaging for neurosurgeries. The world,s ...
Breaking Medicine Technology: